+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase-type plasminogen activator and plasminogen activator inhibitors in human brain tumors



Urokinase-type plasminogen activator and plasminogen activator inhibitors in human brain tumors



Proceedings of the American Association for Cancer Research Annual Meeting 34: 80




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144247

Download citation: RISBibTeXText


Related references

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Journal of Urology 174(2): 461-465, 2005

Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Wound Repair & Regeneration 9(4): 314-322, July-August, 2001

Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Fibrinolysis. 8(Suppl. 1): 61, 1994

Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 in human brain tumors primary cultures. Fibrinolysis 10(Suppl. 3): 138, 1996

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecologic Oncology 79(2): 244-250, 2000

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. American Journal Of Obstetrics & Gynecology. 170(2): 671-676, 1994

Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines. Febs Letters. 383(3): 139-144, 1996

Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochirurgica 140(4): 377-386, 1998